EGFR and lung carcinoma: Studies have shown that non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer types; the sensitive mutation rate of adenocarcinoma tissue in patients with advanced NSCLC patients in mainland China is 48.0%, and the overall epidermal growth factor receptor (EGFR) mutation rate is 50.2% [2].